The emergence of drugs like copyright and Semaglutide signifies a significant shift in how we treat metabolic disorders. These new therapies belong to a class known as GLP-1 target agonists, which mimic the effects of a natural hormone that manages blood sugar levels and hunger. Originally, developed for diabetes, their effectiveness in promoting s